Replay available

Cara Therapeutics, Inc. (CARA) Q1 2023 Earnings Call

Cara Therapeutics, Inc. (NASDAQ: CARA) Q1 2023 earnings conference call, held 2023-05-15. Replay captured from the company's public earnings webcast.

Mon, May 15, 2023 at 4:30 PMendedReplay
Cara Therapeutics, Inc. (CARA) Q1 2023 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Matt Murphy

Manager of Investor Relations

Chris Posner

Chief Executive Officer

Ryan Maynard

Chief Financial Officer

Joseph Stringer

Analyst, Needham & Company

Annabel Simimi

Analyst, Stiefel

Dr. Joanna Consalves

Chief Medical Officer

Jason Gerberry

Analyst, Bank of America Securities

Sumant Kulkarni

Analyst, Canaccord Genuity

Replay transcript excerpt

Good afternoon. My name is Lateef, and I will be your conference facilitator. I would like to welcome everyone to the CARA Therapeutics first quarter financial results and update conference call. All lines have been placed on mute to avoid any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star and the number 1-1 on your telephone keypad. To remove your name from the queue, simply press star and the number 11 again. Please be advised that this call is being recorded. I would now like to introduce Matt Murphy, CARA's Manager of Investor Relations. Mr. Murphy, you may begin your call. Thank you, Operator, and good afternoon. After market closed today, CARA issued a news release announcing the company's financial and operating results for the first quarter of 2023. Copies of this news release and the associated SEC filing can be found in the investor section of our website at www.caratherapeutics.com. Before we begin, let me remind you that during the course of this conference call, we will be making certain forward-looking statements about CARA and our programs based on management's current plans and expectations. These statements are being made under the Private Securities Litigation Reform Act of 1995, and are subject to risks and uncertainties. Actual results may differ materially due to various factors, and CARA undertakes no obligation to update or revise these statements publicly as a result of new information or future results or developments. Investors should read the risk factors set forth in CARA's 10-K for the year ended December 31, 2022, and any subsequent reports filed with the SEC including its Form 10-Q for the quarter ended March 31st, 2023. ...

More from Tvardi Therapeutics, Inc.